182 related articles for article (PubMed ID: 21851216)
21. Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells.
Yin CC; Tang G; Lu G; Feng X; Keating MJ; Medeiros LJ; Abruzzo LV
Mod Pathol; 2015 Aug; 28(8):1130-7. PubMed ID: 25953391
[TBL] [Abstract][Full Text] [Related]
22. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
[TBL] [Abstract][Full Text] [Related]
23. CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
Perkins B; Showel M; Schoch L; Imus PH; Karantanos T; Yonescu R; Morsberger L; Ghiaur G; Gladstone DE; Jones RJ
Leuk Lymphoma; 2022 Jul; 63(7):1617-1623. PubMed ID: 35343368
[TBL] [Abstract][Full Text] [Related]
24. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
[TBL] [Abstract][Full Text] [Related]
25. Immunoglobulin heavy chain variable region gene repertoire and B-cell receptor stereotypes in Indian patients with chronic lymphocytic leukemia.
Rani L; Mathur N; Gogia A; Vishnubhatla S; Kumar L; Sharma A; Dube D; Kaur P; Gupta R
Leuk Lymphoma; 2016 Oct; 57(10):2389-400. PubMed ID: 26942309
[TBL] [Abstract][Full Text] [Related]
26. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
Abramenko I; Bilous N; Kryachok I; Filonenko I; Pilipenko G; Chumak A; Bazyka D; Bebeshko V
Exp Oncol; 2007 Sep; 29(3):226-30. PubMed ID: 18004251
[TBL] [Abstract][Full Text] [Related]
27. Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia.
Stanganelli C; Travella A; Bezares R; Slavutsky I
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):447-457.e2. PubMed ID: 23665144
[TBL] [Abstract][Full Text] [Related]
28. A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion.
Miao Y; Miao Y; Shi K; Sun Q; Zhao SS; Xia Y; Qin SC; Qiu HR; Yang H; Xu H; Zhu HY; Wu JZ; Wu W; Cao L; Wang L; Fan L; Xu W; Li JY
Ann Hematol; 2018 Sep; 97(9):1663-1669. PubMed ID: 29736587
[TBL] [Abstract][Full Text] [Related]
29. Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia.
Rout ED; Burnett RC; Labadie JD; Yoshimoto JA; Avery AC
PLoS One; 2018; 13(1):e0191205. PubMed ID: 29385200
[TBL] [Abstract][Full Text] [Related]
30. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
31. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
32. CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.
Gonzalez D; Else M; Wren D; Usai M; Buhl AM; Parker A; Oscier D; Morgan G; Catovsky D
Haematologica; 2013 Feb; 98(2):274-8. PubMed ID: 22899580
[TBL] [Abstract][Full Text] [Related]
33. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
[TBL] [Abstract][Full Text] [Related]
34. The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study.
Stamatopoulos B; Smith T; Crompot E; Pieters K; Clifford R; Mraz M; Robbe P; Burns A; Timbs A; Bruce D; Hillmen P; Meuleman N; Mineur P; Firescu R; Maerevoet M; De Wilde V; Efira A; Philippé J; Verhasselt B; Offner F; Sims D; Heger A; Dreau H; Schuh A
Clin Cancer Res; 2018 Oct; 24(20):5048-5057. PubMed ID: 29945996
[No Abstract] [Full Text] [Related]
35. NOTCH1 mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases.
Zou Y; Fan L; Xia Y; Miao Y; Wu W; Cao L; Wu J; Zhu H; Qiao C; Wang L; Xu W; Li J
Cancer Med; 2018 May; 7(5):1689-1696. PubMed ID: 29573199
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
38. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia.
Heerema NA; Muthusamy N; Zhao Q; Ruppert AS; Breidenbach H; Andritsos LA; Grever MR; Maddocks KJ; Woyach J; Awan F; Long M; Gordon A; Coombes C; Byrd JC
Haematologica; 2021 Jun; 106(6):1608-1615. PubMed ID: 32414849
[TBL] [Abstract][Full Text] [Related]
40. [Mutational features of immunoglobulin heavy chain variable region gene in patients with chronic lymphocytic leukemia].
Li YH; Huang XQ; Lin YN; Chen XJ; Chen L; Liu EB; Mi YC; Ru K
Zhonghua Bing Li Xue Za Zhi; 2022 Nov; 51(11):1135-1140. PubMed ID: 36323543
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
